Literature DB >> 32317704

High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities.

Youran Zou1, Gulisa Turashvili2,3, Robert A Soslow4, Kay J Park4, Sabrina Croce5, W Glenn McCluggage6, Colin J R Stewart7,8, Yoshinao Oda9, Esther Oliva10,11, Robert H Young10,11, Arnaud Da Cruz Paula12, Kimberly Dessources12, Charles W Ashley12, Martee L Hensley13, Stephen Yip14,15,16, Britta Weigelt4, Ryma Benayed4, Cristina R Antonescu4, Cheng-Han Lee17,18, Sarah Chiang19.   

Abstract

High-grade histologic transformation of low-grade endometrial stromal sarcoma (LGESS) is rare. Here, we describe the clinicopathologic features and gene fusion status of 12 cases (11 primary uterine corpus and 1 primary vaginal), 11 diagnosed prospectively from 2016, and 1 retrospectively collected. Targeted RNA sequencing and/or fluorescence in situ hybridization was employed in all cases. High-grade transformation was seen at the time of initial diagnosis in eight patients and at the time of recurrence in four patients, 4-11 years after initial diagnosis of LGESS. High-grade morphology consisted of generally uniform population of round to epithelioid cells with enlarged nuclei one to two times larger than a lymphocyte, visible nucleoli, and increased mitotic index (range, 6-30; median, 16 per 10 high-power fields); there was often an associated sclerotic and/or myxoid stroma. Estrogen receptor, progesterone receptor, and CD10 expression was absent or significantly decreased (compared with the low-grade component) in the high-grade foci of five tumors. One tumor demonstrated positive (diffuse and strong) cyclin D1 and BCOR staining. p53 staining was wild type in both components of all eight tumors tested. JAZF1-SUZ12 (n = 6), JAZF1-PHF1 (n = 3), EPC1-PHF1, (n = 1), or BRD8-PHF1 (n = 1) fusions were detected in 11 tumors; no fusions were found in one by targeted RNA sequencing. Patients presented with FIGO stages I (n = 4), II (n = 4), III (n = 1), and IV disease (n = 2). Median overall survival calculated from the time of histologic transformation was 22 months (range, 8 months to 8 years) with five patients who died of disease 8-18 months after transformation. High-grade transformation may occur in LGESS with JAZF1 and PHF1 rearrangements at the time of or years after initial diagnosis. Such high-grade transformation is characterized by nuclear enlargement, prominent nucleoli, and increased mitotic index compared with typical LGESS. Histologic high-grade transformation may herald aggressive behavior.

Entities:  

Year:  2020        PMID: 32317704     DOI: 10.1038/s41379-020-0535-y

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

1.  Recurrent KAT6B/A::KANSL1 Fusions Characterize a Potentially Aggressive Uterine Sarcoma Morphologically Overlapping With Low-grade Endometrial Stromal Sarcoma.

Authors:  Abbas Agaimy; Blaise A Clarke; David L Kolin; Cheng-Han Lee; Jen-Chieh Lee; W Glenn McCluggage; Patrik Pöschke; Robert Stoehr; David Swanson; Gulisa Turashvili; Matthias W Beckmann; Arndt Hartmann; Cristina R Antonescu; Brendan C Dickson
Journal:  Am J Surg Pathol       Date:  2022-05-17       Impact factor: 6.298

2.  ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment.

Authors:  Britta Weigelt; Sarah Chiang; Kimberly Dessources; Kathryn M Miller; Elizabeth Kertowidjojo; Arnaud Da Cruz Paula; Youran Zou; Pier Selenica; Edaise M da Silva; Ryma Benayed; Charles W Ashley; Nadeem R Abu-Rustum; Snjezana Dogan; Robert A Soslow; Martee L Hensley
Journal:  Mod Pathol       Date:  2021-12-27       Impact factor: 8.209

3.  Low-Grade Uterine Endometrial Stromal Sarcoma: Prognostic Analysis of Clinico-Pathological Characteristics, Surgical Management, and Adjuvant Treatments. Experience From Two Referral Centers.

Authors:  Fulvio Borella; Luca Bertero; Paola Cassoni; Elisa Piovano; Niccolò Gallio; Mario Preti; Stefano Cosma; Domenico Ferraioli; Luca Pace; Luca Mariani; Nicoletta Biglia; Chiara Benedetto
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

4.  Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma.

Authors:  Amir Momeni-Boroujeni; Nissreen Mohammad; Robert Wolber; Stephen Yip; Martin Köbel; Brendan C Dickson; Martee L Hensley; Mario M Leitao; Cristina R Antonescu; Ryma Benayed; Marc Ladanyi; Cheng-Han Lee; Sarah Chiang
Journal:  Mod Pathol       Date:  2020-10-19       Impact factor: 7.842

Review 5.  Molecular pathogenesis and prognostication of "low-grade'' and "high-grade" endometrial stromal sarcoma.

Authors:  Francesca Micci; Sverre Heim; Ioannis Panagopoulos
Journal:  Genes Chromosomes Cancer       Date:  2020-11-10       Impact factor: 5.006

Review 6.  Fusion genes in gynecologic tumors: the occurrence, molecular mechanism and prospect for therapy.

Authors:  Bingfeng Lu; Ruqi Jiang; Bumin Xie; Wu Wu; Yang Zhao
Journal:  Cell Death Dis       Date:  2021-08-11       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.